Abstract
Technetium-99m-d,l-hexamethylpropylene amine oxime (Tc-99m-HMPAO) has been developed in our Institute in order to meet the demand of GDR clinicians for a radiopharmaceutical, which allows the examination of regional cerebral blood-flow by SPECT. The present paper informs on synthesis and 13C NMR spectroscopic identification of the ligand d,l-HMPAO as well as its labelling by reconstitution of a sterile, freeze-dried mixture containing d,l-HMPAO, stannous chloride, and sodium chloride with Tc-99m-pertechnetate eluate. Labelling efficiency (more than 90%, the lipophilic component 80–90%) and pattern of products were estimated using tlc and paper chromatography with a combination of three solvent systems. Quality control of the freeze-dried formulation includes methods for quantitative determination of the ligand and of stannous chloride. The ability of Tc-99m-HMPAO to be localized in brain was quantified in rats by organ distribution with time and by autoradiography, showing both high initial uptake, and bl...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Isotopenpraxis Isotopes in Environmental and Health Studies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
